To include your compound in the COVID-19 Resource Center, submit it here.

Edurant rilpivirine: Additional Phase III data

Additional data from the double-blind, international Phase III ECHO trial in 690 treatment-naïve HIV patients showed that 83% of patients receiving either 25 mg oral Edurant

Read the full 260 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE